Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT03541902. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Cabosun Ii: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma
Study identification
- NCT ID
- NCT03541902
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 32 participants
Conditions and interventions
Conditions
- Chromophobe Renal Cell Carcinoma
- Malignant Neoplasms of Urinary Tract
- Metastatic Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma
- Renal Cell Carcinoma
- Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions
- Sarcomatoid Renal Cell Carcinoma
- Stage IV Renal Cell Cancer AJCC v8
- Unclassified Renal Cell Carcinoma
Interventions
- Cabozantinib Drug
- Sunitinib Malate Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 14, 2018
- Primary completion
- Jul 30, 2027
- Completion
- Jul 30, 2027
- Last update posted
- Jan 8, 2026
2018 – 2027
United States locations
- U.S. sites
- 3
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| MD Anderson Regional Care Center-Katy | Houston | Texas | 77094 | — |
| MD Anderson Regional Care Center-Sugar Land | Sugar Land | Texas | 77478 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03541902, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03541902 live on ClinicalTrials.gov.